Related Experiment Video

Updated: Apr 29, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K

Optimizing chemotherapy in triple-negative breast cancer: the role of platinum

Melinda Telli1

  • 1From the Stanford University School of Medicine, Division of Oncology, Stanford, CA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 27, 2014
PubMed

Insights

Platinum chemotherapy shows promise for treating triple-negative breast cancer (TNBC) by targeting DNA repair defects. Further research and clinical trials are needed to confirm its effectiveness and optimal use in TNBC patients.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is a challenging subtype with limited targeted therapies.
  • mRNA gene expression profiling has provided insights, but targeting DNA repair defects is a newer strategy.
  • Germline and somatic genetic alterations in TNBC are being investigated for therapeutic vulnerabilities.

Purpose of the Study:

  • To evaluate the potential role of platinum-based chemotherapy in treating TNBC.
  • To explore the utility of targeting DNA repair deficiencies in TNBC.
  • To identify biomarkers for predicting response to platinum therapy in TNBC.

Main Methods:

  • Review of preclinical and clinical data on platinum chemotherapy in TNBC.
  • Analysis of studies focusing on germline and somatic genetic alterations in TNBC.
  • Consideration of randomized clinical trials incorporating biomarkers of response.

Main Results:

  • Growing evidence suggests platinum chemotherapy may benefit both early-stage and advanced TNBC.
  • Current results are not yet definitive, indicating a need for further investigation.
  • Biomarkers such as BRCA1/2 mutations and genomic scarring are crucial for assessing platinum efficacy.

Conclusions:

  • Platinum chemotherapy represents a potential therapeutic strategy for TNBC, particularly in tumors with DNA repair defects.
  • Randomized clinical trials are essential to confirm the optimal use and efficacy of platinum agents in TNBC.
  • Incorporating biomarkers will refine patient selection and treatment strategies for platinum-based therapies in TNBC.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81